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A new analytical method for determining deoxycytidine kinase (dCK) activity in biological
milieus using luminescence is reported here. This method, based on utilizing adenosine
triphosphate (ATP) as the sole phosphate donor in the kinase reaction and monitoring ATP
consumption via a luciferase-based chemiluminescence reaction, is capable of detecting
dCK activity without the use of specific substrates or radioisotope techniques. Comparing
with the reverse-phase high-performance liquid chromatography method, this new
method is suggested to be efficient and sensitive. Further, application of the proposed
method for profiling dCK activity in cultured cancer cells revealed that a cervix cell line
exhibited the highest dCK activity to gemcitabine metabolism.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license. 1. Introduction gemcitabine therapy and resistance to the drug [5e10]. TheDeoxycytidine kinase (dCK) is an enzyme expressed in
eukaryotic cells [1,2] that catalyzes phosphate transfer be-
tween adenosine triphosphate (ATP) and 20-deoxynucleosides.
It plays an essential role in the salvage pathway of nucleotide
metabolism. Therapeutically, dCK phosphorylates anticancer
nucleoside analogs such as gemcitabine (20,20-difluorodeox-
ycytidine) [3] and 2-chlorodeoxyadenosine (CdA) to their
cytotoxic forms [4], which are effective chemotherapeutic
agents for some solid tumors and leukemia. Clinically, dCK is
reported to play a role in mediating the effectiveness of
nucleoside antimetabolite therapies [5e7].
Cumulative pharmacological and pharmacogenetical data
indicate that dCK activity correlates with both efficacy oft, Taipei City, Taiwan, RO
. Hsu).
ministration, Taiwan. PubldCK overexpression increased the sensitivity of colon, breast,
and lung cancer cells to gemcitabine [7,11]; by contrast, dCK
downregulation enhanced acquired drug resistance in
pancreatic cells [6,11]. Levels of dCK protein expression in
human pancreatic cancer tissues are correlated with the
overall survival of the gemcitabine-treated patients [10,12].
The combined evidence suggests that dCK is a versatile
biomarker in nucleoside anticancer therapy and governs the
effectiveness of gemcitabine treatment.
Only a few methods have been established for detecting
dCK in biological samples. Antibody-based methods such as
western blotting and enzyme-linked immunosorbent assay
have limited ability to detect the active form of dCK; therefore,
antibodies that can recognize various dCK substrates areC.
ished by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license. 
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use of radioactive substrates such as [8-3H] CdA and a series of
binding and washing procedures to separate “hot” and “cold”
portions to assess activity [4,14], are complicated with the use
of radioisotope materials, which involves problems such as
waste disposal and radiation safety. Bierau et al [15] developed
a high-performance liquid chromatography (HPLC) method
using nonradiolabeled CdA with inherent limitation in sensi-
tivity because nucleosides have no specific chromophores for
spectrophotometric detection. Therefore, in order to explore
impacts of dCK in pharmacological and clinical studies,
development of an efficient and sensitive method to deter-
mine dCK activity in biological milieus is mandatory.
ATP has been found to serve as the phosphate donor in the
dCK reaction, and ATP analysis is correlated to detect dCK
activity enzymatically (Fig. 1). Several highly sensitive fluo-
rescence and luminescence methods have been developed for
the discovery of kinase inhibitors in preclinical studies [14].
We accordingly developed an efficient luminescent assay for
determining dCK activity in biological milieus. The assay is
based on the use of anion exchange beads to purify dCK from
complex biological samples and a luciferase-based ATP assay
to quantitate dCK activity. With ATP serving as the sole
phosphate donor to dCK substrates in the proposed assayATP conc. (µM)
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Fig. 1 e (A) Reaction scheme of the luminescence dCK
assay. Given that the phosphate transfer reaction
consumes one ATP and one oxygen molecule to produce
one photon of light in the luciferase-based system, the
light measured as RLU is correlated with the amount of
residual ATP and inversely reflects dCK activity. (B) A linear
relationship is observed between the luminescence signal
and ATP concentration. The correlation coefficient (r2) is
0.9941 for ATP in the concentration range of 0.1e10mM.
ADP [ adenosine diphosphate; ATP [ adenosine
triphosphate; dCK[ deoxycytidine kinase; RLU[ Relative
light unit.reaction (Fig. 1), ATP consumption, monitored by a luciferase-
based chemiluminescent reaction, can be utilized to deter-
mine the enzymatic activity of dCK. In the reaction, the
luminescent signal generated from the conversion of beetle
luciferin to oxyluciferin with the stoichiometry of one ATP
molecule to one photon per turnover is inversely correlated to
the dCK activity. This new method has been validated with
comparison to the conventional HPLC method. Its application
in profiling dCK activity in cancer cells has also been
evaluated.2. Methods
2.1. Materials
Deoxycytidine and deoxycytidine triphosphate (dCTP) were
purchased from Sigma-Aldrich (St Louis, MO, USA). Gemcita-
bine (20,20-difluorodeoxycytidine) was obtained from Inno-
pharmax (Taipei, Taiwan). Kinase-Glo reagent was purchased
from Promega (Madison, WI, USA). Other chemicals were of
analytical grades and obtained from Sigma-Aldrich. Milli-Q
water prepared by a Millipore system was used in buffer
preparation.
2.2. Cell lines
HeLa, HCT116, LX-1, 780-O, and MCF-7 cells were obtained
from the American Type Culture Collection (10801 University
Boulevard Manassas, VA 20110 USA). In brief, HeLa and MCF-7
cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM), HCT116 and 786-O cells were cultured in RPMI-1640,
and LX-1 cell was cultured in Minimum Essential Medium.
All media were supplemented with 10% Fetal Bovine Serum
(FBS); and cells were maintained at 37C in 5% CO2 and
routinely passaged every 2e3 days in a 75T flask.
2.3. Protein extraction and quantitation
Cell pellets suspended in extraction buffer (PRO-PREPTM
Protein Extraction solution; iNtRON, Kyunggi-do, Korea) were
sonicated twice on ice for 10 seconds each. After sonication,
extracts were incubated at 20C for 10 minutes and centri-
fuged at 13,628g at 4C for 10 minutes. Supernatants con-
taining the cellular proteins were collected and maintained at
20C prior to analysis.
Protein concentrations of the cell extracts were deter-
mined by a Pierce 660 nm Protein Assay (Thermo, 81 Wyman
Street, Waltham, Massachusetts 02454, USA) using bovine
serum albumin as the protein standard. The calibration curve
was constructed by plotting the optical densities obtained at
660 nm versus the individual known bovine serum albumin
concentration ranging from 0.1 mg/mL to 2.0 mg/mL.
2.4. Developed luminescent assay
To distinguish dCK from other kinases that may interfere
with the assay, a quick purification procedure adapted by
Quan et al [16] was employed. In brief, quantitated cell ex-
tracts containing dCK were incubated with 0.5 mL HiTrap Q
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vial for 1 minute. After binding of dCK to the ion-exchange
beads, the beads were washed with 0.01 M Tris-HCl buffer
(pH 7.0, containing 5 mM b-mercaptoethanol) three times to
remove possible interference proteins. Subsequently, dCK
was eluted by the same Tris-HCl buffer containing 0.5 M
NaCl (0.5 mL) and subjected to the developed luminescent
assay.
To reduce interference from other coeluted proteins, each
sample was divided into two equal parts for the determination
of luminescence signal in the presence or absence of dCK sub-
strate in the assay. Each sample was incubated with 10 mM of
eachdCKsubstrate (deoxycytidineandgemcitabine) andATP in
a 25 mL reaction buffer at 25C for 0e15 minutes for the ATP
consuming assay. At each time point, an equal volume of
Kinase-Glo reagent was added to quench the reaction and
develop the luminescent signal simultaneously at 25C for 10
minutes. The luminescent signal was recorded using a lumi-
nescence microplate reader (Infinite; Tecan, Ma¨nnedorf,
Switzerland) with the integration time set at 0.25 seconds ac-
cording to the manufacturer’s instruction, and the ATP con-
centrations detected between 0 minutes and 4 minutes were
used to calculate the dCK activity after subtracting nonspecific
basal activity, as determined from the blank sample used as a
control. The dCK activity was expressed as nmole/min/mg
protein.
Validation of the developed method was performed using
the linearity, intra- and interday variations, and specificity.
Each sample was analyzed five times using the proposed
method, and the limit of detection and limit of quantification
were calculated as the sample concentration generating a
three- and 10-fold larger luminescence signal than the base-
line noise, respectively.Protein (µg)
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Fig. 2 e (A) Time dependence of the dCK reaction. One
microgram of the dCK-containing sample from rat tissue
(small intestine) was incubated with 10mM gemcitabine2.5. Comparative HPLC method
Biological samples used in the comparative HPLC analysis [15]
were the same as those used in the developed luminescence
assay. In brief, after the kinase reaction was performed
following the above procedures, the samples were quenched
with an equal volume of cold methanol on ice for 10 minutes.
The cold methanolic sample solution was centrifuged at
11,612g at 4C for 10 minutes, and the supernatant was
collected and subjected to HPLC analysis. HPLC runs were
conducted onWaters Model 2695 HPLC system equipped with
an Hypersil OSD-2 column (250mm 4.6mm ID, 5 mmparticle
size) and a variable-wavelength UV detector set at 275 nm.
The mobile phase consisted of phosphate buffer (0.1 M, pH
2.4e2.6) and 2.5 mL 85% phosphoric acid. The injection vol-
ume was 50 mL, and the flow rate of mobile phase was 1.5 mL/
min.and 10mM ATP. The data for each time point represent the
mean of five measurements. (B) ATP consumption versus
dCK activity. Various dCK-containing samples (i.e., 0.25 mg,
0.5 mg, 1 mg, 2.5 mg, and 5 mg) were used to validate the
quantitation relationship. In general, the specific activity of
dCK was calculated on the basis of ATP consumption
between 0 minutes and 4 minutes. ATP [ adenosine
triphosphate; dCK [ deoxycytidine kinase.2.6. Statistical analysis
All experiments were repeated at least three times. Results
were expressed as mean  standard error of the mean. Sta-
tistical significance of differences was assessed by a t test, and
p < 0.05 was considered significant.3. Results
3.1. Development and validation of the proposed dCK
assay
Fig. 1 shows the reaction scheme of the proposed coupled
enzyme assay. Themeasured chemiluminescencewas related
directly to the residual ATP, which inversely corresponds to
dCK activity. Eight known concentrations of ATP solution
were used to establish the linearity of the generated signal.
Highly linear relationship of ATP between 0e10 mM were ob-
tained for the developed dCK assay as the basis of ATP
working concentration with the limit of detection and limit of
quantification of 0.016 mM and 0.048 mM, respectively.
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Fig. 4 e Activity of dCK determined by the developed dCK
assay. The dCK activity of HeLa cells was measured by the
developed method using 10mM gemcitabine (substrate),
10mM ATP (phosphate donor), and 16.5 mg of the dCK-
containing sample from HeLa cells. Measurements were
performed in triplicate with the reaction being quenched at
1 minute, 2 minutes, 4 minutes, 6 minutes, 8 minutes, and
10 minutes. ATP [ adenosine triphosphate;
dCK [ deoxycytidine kinase.
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samples was demonstrated using dCK-containing samples
obtained from rat tissue (small intestine). Based on the stoi-
chiometry between ATP and dCK substrate such as gemcita-
bine, Fig. 2A illustrates that a quantifiable relationship
between ATP consumption and dCK activity was obtained
when the sample was incubated with an exogenous dCK
substrate and ATP. With the ATP consumption by dCK-
containing sample (1 mg) corresponding with dCK activity
after subtracting the basal ATP consumption in the blank
sample, which was assayed without adding a dCK substrate,
dCK activity (nmole/min/mg protein) was calculated easily on
the basis of the ATP consumption rate in the test period (i.e.,
10 minutes). Based on a 4-minute kinetic measurement, the
consumption rate was positively correlated to the amount of
protein added in the range of 0.25e5 mg (Fig. 2B). As the
established relationship was clearly a reflection of kinase ac-
tivity, it is evident that the developed method can be used to
determine dCK activity in a substrate-specific manner.
To further verify the specificity of the developed assay, the
dCK inhibitor dCTP was employed, and it functions as a
feedback competitor with dCK substrates such as gemcitabine
for DNA polymerase [3,16]. As shown in Fig. 3, ATP con-
sumption in the dCK-containing sample was inhibited and
dependent on the various concentrations of dCTP added to the
assay milieus, and 200 mM dCTP inhibited dCK activity by
approximately 70% in a 1 mg dCK-containing sample. These
results suggested that the developed method depicted prop-
erly a quantifiable relationship between luminescence signals
and dCK activity in biological homogenates.A3.2. Activity of dCK determined by the developed method
and a comparative HPLC method
The enzyme dCK is a popular substrate to many pyrimidine
and purine analogs such as gemcitabine. Gemcitabine, for
which an array of decay assays is available, was selected asdCTP conc. (µM)
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Fig. 3 e Inhibition of dCK activity by dCTP. Five
concentrations of dCTP (25 mg, 50 mg, 100 mg, 150 mg, and
200mM) were used to inhibit dCK activity of HeLa cells in
this experiment. ATP [ adenosine triphosphate;
dCK [ deoxycytidine kinase; dCTP [ deoxycytidine
triphosphate.the substrate in the comparative study. The developed lumi-
nescence assay was performed in a white 96-well plate with
protein extracts from human HeLa cells, and Kinase-Glo re-
agent, a commercially available cocktail solution that arrests
the kinase reaction and develops luminescence signal simul-
taneously, was added to determine dCK activity. As shown inTime (min)
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Fig. 5 e Activity of dCK determined by the comparative
high-performance liquid chromatography method. Sample
and reaction condition were the same as that in Fig. 4. (A)
Representative chromatogram of gemcitabine analysis
with a United States Pharmacopeia tailing factor of less
than 1.5. (B) Measurement of dCK activity based on the
kinase reaction quenched at 1 minute, 2 minutes, 4
minutes, and 10 minutes. dCK [ deoxycytidine kinase.
Table 1 e Activity of dCK in cancer cell lines determined
by the developed luminescence assay.
Cell line dCK activity
(nmole/min/mg protein)
Cervix HeLa 3.06  0.96
Colon HCT116 2.96  0.52
Lung LX-1 1.20  0.63
Renal 786-O 2.12  0.07
Breast MCF-7 2.04  0.40
Data are presented as mean  SD of three measurements.
dCK ¼ deoxycytidine kinase; SD ¼ standard deviation.
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determined quickly using a thermostatmicroplate reader. The
amount of residual ATP decreased gradually over time, indi-
cating that the dCK-mediated phosphate transfer reaction
wasmonitored properly by the developed assay. Alternatively,
based on the measurements of substrate decay, the dCK ac-
tivity of the same HeLa cell sample was also determined
comparatively by an HPLC method. Fig. 5 illustrates that as
gemcitabine (with a peak at 9.3minutes) was clearly separated
from other reaction components in the chromatogram, dCK
activity of the same HeLa cell sample was obtained by plotting
the kinetics of gemcitabine decay against time. The gemcita-
bine decay plot was similar to the ATP consumption plot
because dCK mediates phosphorylation of gemcitabine to
gemcitabine monophosphate, and not to its di- or triphos-
phate forms [17].
The highly similar kinetic plots obtained from two
methods suggest that both of themmonitored the same event.
Fig. 6 shows a side-by-side comparison of dCK activity deter-
mined by the two methods. In this figure, the dCK activity
determined by the developed luminescence method was
consistent in two separate reaction periods (0e4 minutes and
0e10 minutes). By contrast, a rapid decay phase resulting in
greater activity was observed in the 0e4-minute reaction
period for the HPLC method, suggesting that this method is
not suitable for detecting a rapid kinase reaction owing to its
time-consuming nature. In particular, the HPLC method is
relatively insensitive for determining dCK activity with
nucleoside analogs, as mentioned previously.
3.3. Profiling dCK activity in cancer cells by the
developed method
After the feasibility of the developedmethodwas confirmed, it
was employed to profile dCK activity in immortal cancer cells,
as dCK is known to determine the efficacy of anticancerFig. 6 e Comparison of the developed dCK assay with a
comparative HPLC method. Measurement of dCK activity
was based on the kinetic data in the periods of 0e4 and
0e10 minutes, whereas dCK activity of HeLa cells
performed by these two methods was compared using a t
test (black bar: the developed dCK assay; gray bar: HPLC
method). dCK [ deoxycytidine kinase; HPLC [ high-
performance liquid chromatography.nucleoside analogs. In addition to HeLa cells, dCK activity was
analyzed in four other cancer cell lines, including the colon
(HCT116), lung (LX-1), renal (786-O), and breast (MCF-7) cancer
cells, by the developed luminescence assay. Table 1 shows
that the dCK activity was 3.06  0.963 nmole/min/mg,
2.96  0.521 nmole/min/mg, 1.20  0.629 nmole/min/mg,
2.12  0.074 nmole/min/mg, and 2.04  0.401 nmole/min/mg
protein in HeLa, HCT116, LX-1, 786-O, and MCF-7 cells,
respectively.4. Discussion
Anticancer nucleoside analogs such as gemcitabine are
among the most effective drugs used in the clinics. To exhibit
therapeutic efficacy, these analogs require cellular uptake
followed by phosphorylation to their cytotoxic nucleotide
forms. Overexpression and/or dysregulation of protein ki-
nases such as dCK has been proved to affect the severity of
disease and efficacy of drug therapy, explaining our interest in
developing an efficient and sensitive method to detect dCK
activity in biological milieus. The traditional biochemical
method used to assay dCK activity in biological matrices is the
radioisotope filtration binding assay [4,14], which is always
complicated with the handling of isotopes in routine studies.
In this study, we developed a luminescence kinase assay
for measuring dCK activity in biological samples such as ani-
mal tissues and immortal cancer cell lines. The feasibility of
the high-throughput enzymatic assay was demonstrated by
the following: (1) its high sensitivity for dCK activity based on
corresponding ATP consumption; (2) ideal kinetics of enzy-
matic reaction including its time and concentration depen-
dence; and (3) high specificities for the substrate (gemcitabine)
and inhibitor (dCTP). In addition, suitability of the developed
method for biological samples was validated by comparing it
with an HPLC method using the same matrix samples.
The major advantages of the developed method over other
conventional dCK assays are its efficiency and speed. For the
developed luminescence assay, a microplate reader was used
to detect the chemiluminescence produced by the couple
enzyme reaction, and the throughput time for ameasurement
was only 0.25 seconds. By contrast, detection time of the
comparative HPLC method, as judged by the separation of
gemcitabine from milieu components, was generally at least
10 minutes. Overall, speed and complexity of detection of dCK
activity in biological samples were improved markedly with
the developed facile luminescence method.
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such as blood or tissue debris and their low sensitivity owing
to a lack of chromophores for nucleosides were resolved by
the developed method. By adopting a simple purification step
using anionic exchanger beads to separate dCK from biolog-
ical contaminants [16], dCK activity in animal tissue can be
determined easily, as shown in this study. By contrast, current
methods either assay dCK in its pure state or employ filtration
and chromatographic procedures to detect dCK in biological
matrices. The newly developed method appears to inherit the
advantages of chemiluminescence detection techniques,
permitting the detection of ATP consumption in blood sam-
ples. Furthermore, sensitivity of the developed luminescence
method was satisfactory using a minimal amount of sample
(protein extract from a well rather than from a flask of cells)
for the analysis. We accordingly anticipate a wide application
of the developed method to biomarker exploration; further
application of this method to improve in vivo anticancer drug
efficacy is underway in our laboratory.Acknowledgments
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